On the origins of three-dimensionality in drug-like molecules

webinar

Thu, 20 Oct 2016, 17:00 CEST (Berlin)

Dr. Nathan Brown, The Institute of Cancer Research, London, UK

On the origins of three-dimensionality in drug-like molecules

Many medicinal chemistry-relevant structures and core scaffolds tend toward geometric planarity, which hampers the optimization of physicochemical properties desirable in drug-like molecules. As challenging drug target classes emerge, the exploitation of molecular three-dimensionality in lead optimization is becoming increasingly important. While recent interest has emphasized the importance of enhanced three-dimensionality in molecular fragment designs, the extent to which this is required in core scaffolds remains unclear.

Three computational methods, Scaffold Tree deconstruction, Synthetic Disconnection Rules retrosynthetic deconstruction and virtual library enumeration, are applied, together with the descriptors plane of best fit and principal moments of inertia, to investigate the origins of three-dimensionality in drug-like molecules. This study informs on the stage at which molecular three-dimensionality should be considered in drug design and highlights key learning that is anticipated to enhance medicinal chemistry design in the future.

Current news

What's So Special About The 'Activity Spotter'? Detailed Insights Into SeeSAR's New Mode
April 29, 2026 10:22 CEST
SeeSAR’s Activity Spotter Mode is designed to dismantle the barrier of raw data and actionable SAR. It helps to answer the most relevant fields in hit-to-lead and lead optimization campaigns: 3D SAR and pharmacophore modeling. Which structural features in my molecule set are associated with activity? Which ones are linked...
Read on
Tool of the Month - FlexX
April 29, 2026 08:53 CEST
Spring is Molecular Docking Season The bread and butter of computational chemistry: predicting potential binding modes, which serves as a crucial foundation for SAR analysis and design decisions, is being made available to everyone this month with the proprietary docking tool FlexX. Validated by over 10,000 citations of its original...
Read on
The 95 Billion Update: Access the REAL Space
April 9, 2026 13:57 CEST
The latest update of Enamine’s REAL Space brings a new expansion, now featuring over 94.5 billion accessible, drug-like products, approaching the 100 billion mark. Built from 173 curated reaction protocols and 202,620 in-stock reagents and building blocks based on Enamine’s in-house knowledge, this version further enhances the world’s largest commercially...
Read on